nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.09.2014 | NON-THEMATIC REVIEW

Circulating tumour cells—a bona fide cause of metastatic cancer

verfasst von: N. J. Caixeiro, N. Kienzle, S. H. Lim, K. J. Spring, A. Tognela, K. F. Scott, P. de Souza, T. M. Becker

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2-3/2014

Einloggen, um Zugang zu erhalten

Abstract

Circulating tumour cells (CTCs) are emerging as important prognostic markers and have potential clinical utility as tumour biomarkers for targeted cancer therapy. Although CTCs were proposed more than 100 years ago as potential precursors that may form metastatic lesions, formal evidence that CTCs are indeed capable of initiating metastases is limited. Moreover, the process of CTCs shedding into the circulation, relocating to distant organ sites and initiating metastatic foci is complex and intrinsically inefficient. To partially explain the metastatic process, the concepts of CTCs as metastatic precursors or pre-metastatic conditioners have been proposed; however, it is questionable as to whether these are both variable pathways to metastasis or just markers of metastatic burden. This review explores the evidence for CTCs in the initiation and progression of metastatic cancer and the data supporting these different concepts in an attempt to better understand the role of CTCs in metastasis. A greater understanding of the metastatic potential of CTCs will open new avenues for therapeutic interventions in the future.

Cohen, S. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., et al. (2009). Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Annals of Oncology, 20(7), 1223–1229. doi:10.1093/annonc/mdn786.PubMedCrossRef

Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., et al. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine, 351(8), 781–791. doi:10.1056/NEJMoa040766.PubMedCrossRef

Pierga, J. Y., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., et al. (2012). High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Annals of Oncology, 23(3), 618–624. doi:10.1093/annonc/mdr263.PubMedCrossRef

Thalgott, M., Rack, B., Maurer, T., Souvatzoglou, M., Eiber, M., Kress, V., et al. (2013). Detection of circulating tumor cells in different stages of prostate cancer. Journal of Cancer Research and Clinical Oncology, 139(5), 755–763. doi:10.1007/s00432-013-1377-5.PubMedCrossRef

Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., et al. (2006). Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clinical Cancer Research, 12(14 Pt 1), 4218–4224. doi:10.1158/1078-0432.CCR-05-2821.PubMedCrossRef

Scher, H. I., Jia, X., de Bono, J. S., Fleisher, M., Pienta, K. J., Raghavan, D., et al. (2009). Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncology, 10(3), 233–239. doi:10.1016/S1470-2045(08)70340-1.PubMedCentralPubMedCrossRef

Dong, X., Alpaugh, K. R., & Cristofanilli, M. (2012). Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. Chinese Journal of Cancer Research, 24(4), 388–398. doi:10.3978/j.issn.1000-9604.2012.11.03.PubMedCentralPubMedCrossRef

Khan, M. S., Kirkwood, A., Tsigani, T., Garcia-Hernandez, J., Hartley, J. A., Caplin, M. E., et al. (2013). Circulating tumor cells as prognostic markers in neuroendocrine tumors. Journal of Clinical Oncology, 31(3), 365–372. doi:10.1200/JCO.2012.44.2905.PubMedCrossRef

Giuliano, M., Giordano, A., Jackson, S., Hess, K. R., De Giorgi, U., Mego, M., et al. (2011). Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research, 13(3), R67. doi:10.1186/bcr2907.PubMedCentralPubMedCrossRef

10.

Lucci, A., Hall, C. S., Lodhi, A. K., Bhattacharyya, A., Anderson, A. E., Xiao, L., et al. (2012). Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncology, 13(7), 688–695. doi:10.1016/S1470-2045(12)70209-7.PubMedCrossRef

11.

Aggarwal, C., Meropol, N. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D., et al. (2013). Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Annals of Oncology, 24(2), 420–428. doi:10.1093/annonc/mds336.PubMedCrossRef

12.

Miyamoto, D. T., Lee, R. J., Stott, S. L., Ting, D. T., Wittner, B. S., Ulman, M., et al. (2012). Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discovery, 2(11), 995–1003. doi:10.1158/2159-8290.CD-12-0222.PubMedCentralPubMedCrossRef

13.

Ashworth, T. R. (1869). A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australian Medical Journal, 14, 146–147.

14.

Valastyan, S., & Weinberg, R. A. (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell, 147(2), 275–292. doi:10.1016/j.cell.2011.09.024.PubMedCentralPubMedCrossRef

15.

Fidler, I. J. (2002). The organ microenvironment and cancer metastasis. Differentiation, 70(9–10), 498–505. doi:10.1046/j.1432-0436.2002.700904.x.PubMedCrossRef

16.

Paget, S. (1889). The distribution of secondary growths in cancer of the breast. Lancet, 1, 571–573.CrossRef

17.

Baccelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., et al. (2013). Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnology, 31(6), 539–544. doi:10.1038/nbt.2576.PubMedCrossRef

18.

Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., et al. (2004). Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research, 10(24), 8152–8162. doi:10.1158/1078-0432.CCR-04-1110.PubMedCrossRef

19.

Tiwari, N., Gheldof, A., Tatari, M., & Christofori, G. (2012). EMT as the ultimate survival mechanism of cancer cells. Seminars in Cancer Biology, 22(3), 194–207. doi:10.1016/j.semcancer.2012.02.013.PubMedCrossRef

20.

Nieto, M. A., & Cano, A. (2012). The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Seminars in Cancer Biology, 22(5–6), 361–368. doi:10.1016/j.semcancer.2012.05.003.PubMedCrossRef

21.

Lindemann, F., Schlimok, G., Dirschedl, P., Witte, J., & Riethmuller, G. (1992). Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet, 340(8821), 685–689.PubMedCrossRef

22.

Vogel, P., Ruschoff, J., Kummel, S., Zirngibl, H., Hofstadter, F., Hohenberger, W., et al. (2000). Prognostic value of microscopic peritoneal dissemination: comparison between colon and gastric cancer. Diseases of the Colon and Rectum, 43(1), 92–100.PubMedCrossRef

23.

de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14(19), 6302–6309. doi:10.1158/1078-0432.CCR-08-0872.PubMedCrossRef

24.

De Giorgi, U., Mego, M., Scarpi, E., Giuliano, M., Giordano, A., Reuben, J. M., et al. (2012). Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clinical Breast Cancer, 12(4), 264–269. doi:10.1016/j.clbc.2012.04.004.PubMedCrossRef

25.

Hiltermann, T. J., Pore, M. M., van den Berg, A., Timens, W., Boezen, H. M., Liesker, J. J., et al. (2012). Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Annals of Oncology, 23(11), 2937–2942. doi:10.1093/annonc/mds138.PubMedCrossRef

26.

Hou, J. M., Krebs, M. G., Lancashire, L., Sloane, R., Backen, A., Swain, R. K., et al. (2012). Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. Journal of Clinical Oncology, 30(5), 525–532. doi:10.1200/JCO.2010.33.3716.PubMedCrossRef

27.

Nieva, J., Wendel, M., Luttgen, M. S., Marrinucci, D., Bazhenova, L., Kolatkar, A., et al. (2012). High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Physical Biology, 9(1), 016004. doi:10.1088/1478-3975/9/1/016004.PubMedCentralPubMedCrossRef

28.

Luzzi, K. J., MacDonald, I. C., Schmidt, E. E., Kerkvliet, N., Morris, V. L., Chambers, A. F., et al. (1998). Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. American Journal of Pathology, 153(3), 865–873. doi:10.1016/S0002-9440(10)65628-3.PubMedCentralPubMedCrossRef

29.

Mervic, L. (2012). Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS ONE, 7(3), e32955. doi:10.1371/journal.pone.0032955.PubMedCentralPubMedCrossRef

30.

Tas, F. (2012). Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis. Onkologie, 35(3), 95–98. doi:10.1159/000336812.PubMedCrossRef

31.

Coumans, F. A., Siesling, S., & Terstappen, L. W. (2013). Detection of cancer before distant metastasis. BMC Cancer, 13(1), 283. doi:10.1186/1471-2407-13-283.PubMedCentralPubMedCrossRef

32.

Ito, S., Nakanishi, H., Ikehara, Y., Kato, T., Kasai, Y., Ito, K., et al. (2001). Real-time observation of micrometastasis formation in the living mouse liver using a green fluorescent protein gene-tagged rat tongue carcinoma cell line. International Journal of Cancer, 93(2), 212–217. doi:10.1002/ijc.1318.CrossRef

33.

Weiss, L. (2000). Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer and Metastasis Reviews, 19(3-4), I–XI. 193-383.PubMed

34.

Becker, T. M., Caixeiro, N. J., Lim, S. H., Tognela, A., Kienzle, N., Scott, K. F., et al. (2014). New frontiers in circulating tumor cell analysis: a reference guide for biomolecular profiling toward translational clinical use. International Journal of Cancer, 134(11), 2523–2533. doi:10.1002/ijc.28516.CrossRef

35.

Rossi, E., Basso, U., Celadin, R., Zilio, F., Pucciarelli, S., Aieta, M., et al. (2010). M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by cell search analysis. Clinical Cancer Research, 16(21), 5233–5243. doi:10.1158/1078-0432.CCR-10-1449.PubMedCrossRef

36.

Larson, C. J., Moreno, J. G., Pienta, K. J., Gross, S., Repollet, M., & O’Hara, S. M. (2004). Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry Part A, 62(1), 46–53. doi:10.1002/cyto.a.20073.CrossRef

37.

Powell, A. A., Talasaz, A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., et al. (2012). Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE, 7(5), e33788. doi:10.1371/journal.pone.0033788.PubMedCentralPubMedCrossRef

38.

Duda, D. G., Duyverman, A. M., Kohno, M., Snuderl, M., Steller, E. J., Fukumura, D., et al. (2010). Malignant cells facilitate lung metastasis by bringing their own soil. Proceedings of the National Academy of Sciences of the United States of America, 107(50), 21677–21682. doi:10.1073/pnas.1016234107.PubMedCentralPubMedCrossRef

39.

Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9(4), 239–252. doi:10.1038/nrc2618.PubMedCentralPubMedCrossRef

40.

Honn, K. V., Tang, D. G., & Crissman, J. D. (1992). Platelets and cancer metastasis: a causal relationship? Cancer and Metastasis Reviews, 11(3–4), 325–351.PubMedCrossRef

41.

Palumbo, J. S., Talmage, K. E., Massari, J. V., La Jeunesse, C. M., Flick, M. J., Kombrinck, K. W., et al. (2005). Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood, 105(1), 178–185. doi:10.1182/blood-2004-06-2272.PubMedCrossRef

42.

Erpenbeck, L., Nieswandt, B., Schon, M., Pozgajova, M., & Schon, M. P. (2010). Inhibition of platelet GPIb alpha and promotion of melanoma metastasis. Journal of Investigative Dermatology, 130(2), 576–586. doi:10.1038/jid.2009.278.PubMedCrossRef

43.

Hafner, M., Orosz, P., Kruger, A., & Mannel, D. N. (1996). TNF promotes metastasis by impairing natural killer cell activity. International Journal of Cancer, 66(3), 388–392. doi:10.1002/(SICI)1097-0215(19960503)66:3<388::AID-IJC20>3.0.CO;2-6.CrossRef

44.

Steinert, G., Scholch, S., Niemietz, T., Iwata, N., Garcia, S. A., Behrens, B., et al. (2014). Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Research, 74(6), 1694–1704. doi:10.1158/0008-5472.CAN-13-1885.PubMedCrossRef

45.

Shao, B., Wahrenbrock, M. G., Yao, L., David, T., Coughlin, S. R., Xia, L., et al. (2011). Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood, 118(15), 4015–4023. doi:10.1182/blood-2011-07-368514.PubMedCentralPubMedCrossRef

46.

Letai, A., & Kuter, D. J. (1999). Cancer, coagulation, and anticoagulation. The Oncologist, 4(6), 443–449.PubMed

47.

Micalizzi, D. S., Farabaugh, S. M., & Ford, H. L. (2010). Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. Journal of Mammary Gland Biology and Neoplasia, 15(2), 117–134. doi:10.1007/s10911-010-9178-9.PubMedCentralPubMedCrossRef

48.

Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., et al. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology, 2(2), 76–83. doi:10.1038/35000025.PubMedCrossRef

49.

Talbot, L. J., Bhattacharya, S. D., & Kuo, P. C. (2012). Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. International Journal of Biochemistry and Molecular Biology, 3(2), 117–136.PubMedCentralPubMed

50.

Sieuwerts, A. M., Mostert, B., Bolt-de Vries, J., Peeters, D., de Jongh, F. E., Stouthard, J. M., et al. (2011). mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clinical Cancer Research, 17(11), 3600–3618. doi:10.1158/1078-0432.CCR-11-0255.PubMedCrossRef

51.

Yokobori, T., Iinuma, H., Shimamura, T., Imoto, S., Sugimachi, K., Ishii, H., et al. (2013). Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Research, 73(7), 2059–2069. doi:10.1158/0008-5472.CAN-12-0326.PubMedCrossRef

52.

Kallergi, G., Papadaki, M. A., Politaki, E., Mavroudis, D., Georgoulias, V., & Agelaki, S. (2011). Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Research, 13(3), R59. doi:10.1186/bcr2896.PubMedCentralPubMedCrossRef

53.

Balasubramanian, P., Lang, J. C., Jatana, K. R., Miller, B., Ozer, E., Old, M., et al. (2012). Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS ONE, 7(7), e42048. doi:10.1371/journal.pone.0042048.PubMedCentralPubMedCrossRef

54.

Becker, T. M., Caixeiro, N. J., Lim, S. H., Tognela, A., Kienzle, N., Scott, K. F., et al. (2013). New frontiers in circulating tumor cell analysis—a reference guide for biomolecular profiling towards translational clinical use. International Journal of Cancer. doi:10.1002/ijc.28516.

55.

Giordano, A., Gao, H., Anfossi, S., Cohen, E., Mego, M., Lee, B. N., et al. (2012). Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Molecular Cancer Therapeutics, 11(11), 2526–2534. doi:10.1158/1535-7163.MCT-12-0460.PubMedCentralPubMedCrossRef

56.

Mego, M., Mani, S. A., Lee, B. N., Li, C., Evans, K. W., Cohen, E. N., et al. (2012). Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. International Journal of Cancer, 130(4), 808–816. doi:10.1002/ijc.26037.CrossRef

57.

Satelli, A., Mitra, A., Cutrera, J. J., Devarie, M., Xia, X., Ingram, D. R., et al. (2014). Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Research, 74(6), 1645–1650. doi:10.1158/0008-5472.CAN-13-1739.PubMedCrossRef

58.

Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50–56. doi:10.1038/35065016.PubMedCrossRef

59.

Craig, M. J., & Loberg, R. D. (2006). CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer and Metastasis Reviews, 25(4), 611–619. doi:10.1007/s10555-006-9027-x.PubMedCrossRef

60.

Thiery, J. P. (2003). Epithelial-mesenchymal transitions in development and pathologies. Current Opinion in Cell Biology, 15(6), 740–746.PubMedCrossRef

61.

Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2(8), 563–572. doi:10.1038/nrc865.PubMedCrossRef

62.

Pantel, K., & Brakenhoff, R. H. (2004). Dissecting the metastatic cascade. Nature Reviews Cancer, 4(6), 448–456. doi:10.1038/nrc1370.PubMedCrossRef

63.

Chiang, A. C., & Massague, J. (2008). Molecular basis of metastasis. New England Journal of Medicine, 359(26), 2814–2823. doi:10.1056/NEJMra0805239.PubMedCrossRef

64.

Nierodzik, M. L., & Karpatkin, S. (2006). Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell, 10(5), 355–362. doi:10.1016/j.ccr.2006.10.002.PubMedCrossRef

65.

Gantus, M. A., Alves, L. M., Stipursky, J., Souza, E. C., Teodoro, A. J., Alves, T. R., et al. (2011). Estradiol modulates TGF-beta1 expression and its signaling pathway in thyroid stromal cells. Molecular and Cellular Endocrinology, 337(1–2), 71–79. doi:10.1016/j.mce.2011.02.001.PubMedCrossRef

66.

Heitzer, E., Auer, M., Gasch, C., Pichler, M., Ulz, P., Hoffmann, E. M., et al. (2013). Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Research, 73(10), 2965–2975. doi:10.1158/0008-5472.CAN-12-4140.PubMedCrossRef

67.

Smirnov, D. A., Zweitzig, D. R., Foulk, B. W., Miller, M. C., Doyle, G. V., Pienta, K. J., et al. (2005). Global gene expression profiling of circulating tumor cells. Cancer Research, 65(12), 4993–4997. doi:10.1158/0008-5472.CAN-04-4330.PubMedCrossRef

68.

Shaikhibrahim, Z., Lindstrot, A., Ellinger, J., Rogenhofer, S., Buettner, R., & Wernert, N. (2012). Genes differentially expressed in the peripheral zone compared to the transitional zone of the normal human prostate and their potential regulation by ETS factors. Molecular Medicine Reports, 5(1), 32–36. doi:10.3892/mmr.2011.628.PubMed

69.

Raja, S. B., Murali, M. R., Devaraj, H., & Devaraj, S. N. (2012). Differential expression of gastric MUC5AC in colonic epithelial cells: TFF3-wired IL1 beta/Akt crosstalk-induced mucosal immune response against Shigella dysenteriae infection. Journal of Cell Science, 125(Pt 3), 703–713. doi:10.1242/jcs.092148.PubMedCrossRef

70.

Bidard, F. C., Pierga, J. Y., Vincent-Salomon, A., & Poupon, M. F. (2008). A “class action” against the microenvironment: do cancer cells cooperate in metastasis? Cancer and Metastasis Reviews, 27(1), 5–10. doi:10.1007/s10555-007-9103-x.PubMedCentralPubMedCrossRef

71.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. doi:10.1016/j.cell.2011.02.013.PubMedCrossRef

72.

Vanderlaag, K. E., Hudak, S., Bald, L., Fayadat-Dilman, L., Sathe, M., Grein, J., et al. (2010). Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Research, 12(3), R32. doi:10.1186/bcr2586.PubMedCentralPubMedCrossRef

73.

Khatib, A. M., Auguste, P., Fallavollita, L., Wang, N., Samani, A., Kontogiannea, M., et al. (2005). Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. American Journal of Pathology, 167(3), 749–759. doi:10.1016/S0002-9440(10)62048-2.PubMedCentralPubMedCrossRef

74.

Auguste, P., Fallavollita, L., Wang, N., Burnier, J., Bikfalvi, A., & Brodt, P. (2007). The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. American Journal of Pathology, 170(5), 1781–1792. doi:10.2353/ajpath.2007.060886.PubMedCentralPubMedCrossRef

75.

Liotta, L. A., & Kohn, E. C. (2001). The microenvironment of the tumour-host interface. Nature, 411(6835), 375–379. doi:10.1038/35077241.PubMedCrossRef

76.

Obermayr, E., Castillo-Tong, D. C., Pils, D., Speiser, P., Braicu, I., Van Gorp, T., et al. (2013). Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance—a study of the OVCAD consortium. Gynecologic Oncology, 128(1), 15–21. doi:10.1016/j.ygyno.2012.09.021.PubMedCrossRef

77.

Bidard, F. C., Pierga, J. Y., Soria, J. C., & Thiery, J. P. (2013). Translating metastasis-related biomarkers to the clinic–progress and pitfalls. Nature Reviews Clinical Oncology, 10(3), 169–179. doi:10.1038/nrclinonc.2013.4.PubMedCrossRef

78.

Zhe, X., Cher, M. L., & Bonfil, R. D. (2011). Circulating tumor cells: finding the needle in the haystack. American Journal of Cancer Research, 1(6), 740–751.PubMedCentralPubMed

79.

Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., et al. (2005). A pooled analysis of bone marrow micrometastasis in breast cancer. New England Journal of Medicine, 353(8), 793–802. doi:10.1056/NEJMoa050434.PubMedCrossRef

80.

Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., et al. (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature Medicine, 18(6), 883–891. doi:10.1038/nm.2753.PubMedCentralPubMedCrossRef

81.

Pantel, K., Schlimok, G., Kutter, D., Schaller, G., Genz, T., Wiebecke, B., et al. (1991). Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Research, 51(17), 4712–4715.PubMed

82.

Schlimok, G., & Riethmuller, G. (1990). Detection, characterization and tumorigenicity of disseminated tumor cells in human bone marrow. Seminars in Cancer Biology, 1(3), 207–215.PubMed

83.

Pantel, K., Schlimok, G., Angstwurm, M., Passlick, B., Izbicki, J. R., Johnson, J. P., et al. (1995). Early metastasis of human solid tumours: expression of cell adhesion molecules. Ciba Foundation Symposium, 189, 157–170. discussion 170-153, 174-156.PubMed

84.

Dawson, M. R., Duda, D. G., Fukumura, D., & Jain, R. K. (2009). VEGFR1-activity-independent metastasis formation. Nature, 461(7262), E4. doi:10.1038/nature08254. discussion E5.PubMedCentralPubMedCrossRef

85.

Brandt, B., Junker, R., Griwatz, C., Heidl, S., Brinkmann, O., Semjonow, A., et al. (1996). Isolation of prostate-derived single cells and cell clusters from human peripheral blood. Cancer Research, 56(20), 4556–4561.PubMed

86.

Al-Mehdi, A. B., Tozawa, K., Fisher, A. B., Shientag, L., Lee, A., & Muschel, R. J. (2000). Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nature Medicine, 6(1), 100–102. doi:10.1038/71429.PubMedCrossRef

87.

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine, 366(10), 883–892. doi:10.1056/NEJMoa1113205.PubMedCrossRef

88.

Gasch, C., Bauernhofer, T., Pichler, M., Langer-Freitag, S., Reeh, M., Seifert, A. M., et al. (2013). Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clinical Chemistry, 59(1), 252–260. doi:10.1373/clinchem.2012.188557.PubMedCrossRef

89.

Niikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., et al. (2012). Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. Journal of Clinical Oncology, 30(6), 593–599. doi:10.1200/JCO.2010.33.8889.PubMedCentralPubMedCrossRef

90.

Dupont Jensen, J., Laenkholm, A. V., Knoop, A., Ewertz, M., Bandaru, R., Liu, W., et al. (2011). PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clinical Cancer Research, 17(4), 667–677. doi:10.1158/1078-0432.CCR-10-1133.PubMedCrossRef

Titel: Circulating tumour cells—a bona fide cause of metastatic cancer
verfasst von: N. J. Caixeiro
N. Kienzle
S. H. Lim
K. J. Spring
A. Tognela
K. F. Scott
P. de Souza
T. M. Becker
Publikationsdatum: 01.09.2014
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2-3/2014
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9502-8

Springer Medizin

Circulating tumour cells—a bona fide cause of metastatic cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2-3/2014

Novel drugs targeting the androgen receptor pathway in prostate cancer

Emerging strategies to overcome resistance to endocrine therapy for breast cancer

Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases

Advances in genomic characterization of circulating tumor cells

Emerging technology: applications of Raman spectroscopy for prostate cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie